白细胞介素-12抗肿瘤新生血管生成的研究进展
摘要
白细胞介素-12是由树突状细胞、巨噬细胞和自然杀伤细胞产生的两个二硫键连接蛋白亚基p35和p40组成的一种异二聚体细胞因子。白细胞介素-12有良好的抗炎性,可以发挥抗炎和促炎作用,这取决于不同的炎症微环境。白细胞介素-12是一种具有抗血管生成活性的多向免疫调节细胞因子,对细胞表面分子表达具有调节作用,通过刺激抗血管生成的细胞因子和趋化因子抑制新生血管的形成。肿瘤新生血管的形成是肿瘤发生、生长、浸润和转移的重要条件,目前白细胞介素-12成为抑制肿瘤新生血管的研究热点。因此,进一步研究白细胞介素-12抑制新生血管的机制具有重要意义。本文主要从抗肿瘤方面对白细胞介素-12抑制新生血管增生等方面做一综述。
引文
[1]Silver DF,Hempling RE,Piver MS,et al.Effects of IL-12 on human ovarian tumors engafted into SCID mice[J].Gynecol Oncol,1999,72(2):154-160.Patterson E,Wall R,Fitzgerald GF,et al.Health implications of high dietary omega-6polyunsaturated fatty acids[J].J Nutr Metab,2012,2012:539-542.doi:10.1155/2012/539426.Epub 2012 Apr 5.
[3]Ciomber A,Smagur A,Mitrus I,et al.Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.Arch Immunol Ther Exp,2014,62(2):161-168.
[4]Floss DM,Schr?der J,Franke M,et al.Insights into IL-23 biology:From structure to function[J].Cytokine Growth Factor Rev,2015,26(5):569-578.
[5]Fucikova J,Kralikova P,Fialova A,et al.Human tumor cells killed by anthracyclines induce a tumor-specific immune response[J].Cancer Res,2011,71(14):4821-4833.
[6]Kim CH,Hong MJ,Park SD,et al.Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12[J].Cancer Immunol Immunother,2006,55(11):1309-1319.
[7]Lasek W,Zago?d?on R,Jakobisiak M.Interleukin 12:still a promising candidate for tumor immunotherapy?[J].Cancer Immunol Immunother,2014,63(5):419-435.
[8]Deng J,Younge BR,Olshen RA,et al.Th17 and Th1T-cell responses in giant cell arteritis[J].Circulati on,2010,121(7):906-915.
[9]Chang JH,Gabison EE,Kato T,et al.Corneal neovascularization[J].Curr Opin Ophthalmol,2001,12(4):242-249.
[10]Sivak JM,Ostriker AC,Woolfenden A,et al.Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization[J].J Biol Chem,2011,286(52):44965-44975.
[11]Symes RJ,Poole TR.Corneal graft surgery combined with subconjunctival bevacizumab(Avastin)[J].Cornea,2010,29(6):691-693.
[12]金玲,蔡郑东,楼月芳.内毒素诱导兔角膜新生血管模型实验研究[J].眼科研究,1998,16(2):85-86.
[3]Ciomber A,Smagur A,Mitrus I,et al.Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.Arch Immunol Ther Exp,2014,62(2):161-168.
[4]Floss DM,Schr?der J,Franke M,et al.Insights into IL-23 biology:From structure to function[J].Cytokine Growth Factor Rev,2015,26(5):569-578.
[5]Fucikova J,Kralikova P,Fialova A,et al.Human tumor cells killed by anthracyclines induce a tumor-specific immune response[J].Cancer Res,2011,71(14):4821-4833.
[6]Kim CH,Hong MJ,Park SD,et al.Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12[J].Cancer Immunol Immunother,2006,55(11):1309-1319.
[7]Lasek W,Zago?d?on R,Jakobisiak M.Interleukin 12:still a promising candidate for tumor immunotherapy?[J].Cancer Immunol Immunother,2014,63(5):419-435.
[8]Deng J,Younge BR,Olshen RA,et al.Th17 and Th1T-cell responses in giant cell arteritis[J].Circulati on,2010,121(7):906-915.
[9]Chang JH,Gabison EE,Kato T,et al.Corneal neovascularization[J].Curr Opin Ophthalmol,2001,12(4):242-249.
[10]Sivak JM,Ostriker AC,Woolfenden A,et al.Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization[J].J Biol Chem,2011,286(52):44965-44975.
[11]Symes RJ,Poole TR.Corneal graft surgery combined with subconjunctival bevacizumab(Avastin)[J].Cornea,2010,29(6):691-693.
[12]金玲,蔡郑东,楼月芳.内毒素诱导兔角膜新生血管模型实验研究[J].眼科研究,1998,16(2):85-86.